Endo Announces Successful Term Loan Repricing
Endo has successfully completed the repricing of its $1.5 billion term loan due 2031. The new rate is Term SOFR plus 400 basis points, representing a 50 basis points reduction in the interest rate. This refinancing is expected to generate annual interest expense savings of approximately $8 million. The loan maturity and other terms remain substantially unchanged.
Endo ha completato con successo il rinegoziamento del suo prestito a termine di 1,5 miliardi di dollari in scadenza nel 2031. Il nuovo tasso è il Term SOFR più 400 punti base, che rappresenta una riduzione di 50 punti base nel tasso di interesse. Si prevede che questo rifinanziamento genererà risparmi annuali sulle spese di interessi di circa 8 milioni di dollari. La scadenza del prestito e altre condizioni rimangono sostanzialmente invariate.
Endo ha completado con éxito la reprogramación de su préstamo a plazo de 1.5 mil millones de dólares que vence en 2031. La nueva tasa es Term SOFR más 400 puntos básicos, lo que representa una reducción de 50 puntos básicos en la tasa de interés. Se espera que este refinanciamiento genere ahorros anuales en los gastos de interés de aproximadamente 8 millones de dólares. La fecha de vencimiento del préstamo y otros términos permanecen sustancialmente sin cambios.
Endo는 2031년에 만기가 도래하는 15억 달러 규모의 만기 대출 재가격 조정을 성공적으로 완료했습니다. 새로운 이자율은 Term SOFR에 400 베이시스 포인트를 추가한 것으로, 이는 50 베이시스 포인트 인하를 의미합니다. 이번 재융자는 연간 약 800만 달러의 이자 비용 절감을 가져올 것으로 예상됩니다. 대출 만기 및 기타 조건은 크게 변경되지 않습니다.
Endo a réussi à finaliser la renégociation de son prêt à terme de 1,5 milliard de dollars qui arrive à échéance en 2031. Le nouveau taux est de Term SOFR plus 400 points de base, ce qui représente une réduction de 50 points de base du taux d'intérêt. Ce refinancement devrait générer des économies annuelles d'intérêts d'environ 8 millions de dollars. L'échéance du prêt et d'autres termes restent largement inchangés.
Endo hat erfolgreich die Umschuldung seines 1,5 Milliarden Dollar Terminkredits mit Fälligkeit 2031 abgeschlossen. Der neue Zinssatz beträgt Term SOFR plus 400 Basispunkte, was einer Reduzierung um 50 Basispunkte im Zinssatz entspricht. Es wird erwartet, dass diese Refinanzierung jährliche Zinskostenersparnisse von etwa 8 Millionen Dollar generiert. Die Laufzeit des Kredits und andere Konditionen bleiben weitestgehend unverändert.
- Interest expense reduction of $8 million annually
- Successfully reduced interest rate by 50 basis points on $1.5B term loan
- None.
About Endo
Endo is a diversified specialty pharmaceutical company boldly transforming insights into life-enhancing therapies. Our passionate team members collaborate to develop and deliver these essential medicines. Together, we are committed to helping everyone we serve live their best life. Learn more at www.endo.com or connect with us on LinkedIn.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements including, but not limited to, interest expense savings and any statements that refer to expected, estimated or anticipated future results or that do not relate solely to historical facts. Statements including words such as "believes," "expects," "anticipates," "intends," "estimates," "plan," "will," "may," "look forward," "intends," "guidance," "future," "potential" or similar expressions are forward-looking statements. Because these statements reflect Endo's current views, expectations and beliefs concerning future events, they involve risks and uncertainties, some of which Endo may not currently be able to predict. Although Endo believes that these forward-looking statements and other information are based upon reasonable assumptions and expectations, readers should not place undue reliance on these or any other forward-looking statements and information. Actual results may differ materially and adversely from current expectations based on a number of factors. Endo assumes no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise, except as may be required under applicable securities laws. Additional information concerning risk factors, including those referenced above, can be found in Endo's press releases and in its public filings with the
View original content to download multimedia:https://www.prnewswire.com/news-releases/endo-announces-successful-term-loan-repricing-302290520.html
SOURCE Endo, Inc.
FAQ
How much will Endo (NDOI) save annually from its 2024 term loan repricing?
What is the new interest rate for Endo's (NDOI) $1.5 billion term loan after October 2024 repricing?
When does Endo's (NDOI) repriced term loan mature?
